MELBOURNE, Australia and INDIANAPOLIS — February 20, 2026 — Leads & Copy —
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will participate in two upcoming healthcare conferences.
Managing Director and Group CEO, Dr. Christian Behrenbruch, will participate in a fireside chat with Oppenheimer on Thursday, February 26, 2026, at 4:40 p.m. EST. This corresponds to Friday, Feb 27 at 8:40 a.m. AEDT.
Dr. Behrenbruch will also present at the TD Cowen 46th Annual Health Care Conference in Boston, MA, alongside Kevin Richardson, Chief Executive Officer, Precision Medicine. The presentation is scheduled for Monday, March 2, 2026, at 1:50 p.m. EST, or Tuesday, Mar 3 at 5:50 a.m. AEDT.
Both sessions will be webcast live and accessible through Telix’s Investor Relations website.
Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix has international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. The company is developing a portfolio of clinical and commercial stage products to address unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
More information, including how to register for the webcasts, can be found at https://ir.telixpharma.com/events-presentations.
Source: Telix Pharmaceuticals Limited
